Indeed, several recent studies suggest that AR continues to play a key role in the survival and proliferation of HID prostate cancers via HER2 signalisation (Craft et al, 1999; Yeh et al, 1999), explaining the role of trastuzumab in the combination with docetaxel. This evidence concerns the gene ERBB2 and prostate cancer.